Dynavax Accused Of Duping Investors About Hepatitis Vaccine

Law360, New York (June 19, 2013, 4:20 PM EDT) -- Dynavax Technologies Corp. investors hit the biopharmaceutical company with a putative class action Tuesday alleging it made false statements about its Heplisav vaccine for hepatitis B, causing its share price to plunge after it disclosed that regulators had safety concerns.

The suit, filed in California federal court, says Dynavax's stock traded at artificially high levels last year because the company misrepresented to the public that Heplisav was getting close to a commercial launch, while failing to report that its clinical trials of the vaccine were flawed....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re Dynavax Technologies Corporation Securities Litigation


Case Number

3:13-cv-02796

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

Charles R. Breyer

Date Filed

June 18, 2013

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.